FindTrial
Sign In

To evaluate role of procalcitonin in detecting sepsis in patients with liver failure

Spectrum of infections and efficacy of procalcitonin in detecting sepsis in decompensated cirrhotic patients. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/06/069424
Enrollment
135
Registered
2024-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K742- Hepatic fibrosis with hepatic sclerosis

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 18 years Patients diagnosed with cirrhosis. Patient with evidence of Systemic inflammatory response syndrome and presence of infection.

Exclusion criteria

Exclusion criteria: Patients diagnosed as Acute-on-chronic liver failure as per APASL definition. Patients who are diagnosed with HCC

Design outcomes

Primary

MeasureTime frame
To study the spectrum of various infections in patients with decompensated cirrhosis. Timepoint: 6 months—

Secondary

MeasureTime frame
To assess the efficacy of procalcitonin as a marker in detecting sepsis in patients with decompensated cirrhosis.Timepoint: 6 months—

Countries

India

Contacts

Public ContactDr Suriya KKN

Manipal Academy of Higher Education

bhat.ganesh@manipal.edu9900791615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026